Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals)
Europe Multiple Sclerosis Market, Patients By (United Kingdom, Germany, France, Italy, Spain) By (Injectables, Infusion, Orals) published by Renub Research on Multiple Sclerosis Market.
Get 10% Free Customization in this Report
Europe multiple sclerosis market potential is of more than US$ 5 Billion by 2022. But only more than half this market is expected to be actually achieved. This huge difference between actual market and unmet market is due to gap between number of patients who require multiple sclerosis drugs and number of patients who are receiving disease modifying therapy.
Orals mode of administration is Fast growing disease modifying therapy in the European region
Orals mode of administration is fast growing disease modifying therapy in the European region. Injectables and infusions multiple sclerosis therapies are steadily losing their ground in the European market.
Germany is the clear winner in the Europe multiple sclerosis market
In the Europe multiple sclerosis market, Germany is the clear winner, but its losing its market share year on year. The other important markets in the European region are France, Italy, Spain and United Kingdom.
Request a free sample copy of the report: https://www.renub.com/contactus.php
This 86 page report with 73 figures and 1 Tables provides 5 Countries: actual and unmet patient numbers and market. This report also explains multiple sclerosis disease modifying therapy (DMT) mode of administration.
- Actual Market is the current market which is already present
- Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.
Top 5 Countries Multiple Sclerosis Market & Patients Treated
1. United Kingdom
2. Germany
3. France
4. Italy
5. Spain
Mode of administration - Market & Patients Treated
1. Injectables
2. Infusions
3. Orals
Key Questions Answered in the Report?
- What is the Europe multiple sclerosis market and its growth potential in near future?
- How many number of patients treated by disease modifying therapy in the European region?
- What is the multiple sclerosis market in European countries (UK, Germany, France, Italy, and Spain)?
- How many multiple sclerosis patients living in European countries?
- Which mode of administration (Injectables, Infusions, Orals) is gaining more popularity?
1. Executive Summary
2. Europe Multiple Sclerosis Patient Numbers (2011 – 2022)
2.1 Patient Number & Forecast
2.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3 By Mode of Administration - Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
2.3.1 Injectables Patients Numbers
2.3.2 Infusions Patients Numbers
2.3.3 Orals Patient Numbers
3. Europe Multiple Sclerosis Market (2011 – 2022)
3.1 Unmet Market & Forecast
3.2 Market & Forecast
3.3 By Mode of Administration - Market & Forecast
3.3.1 Injectables Market
3.3.2 Infusions Market
3.3.3 Orals Market
4. Europe Multiple Sclerosis Population Share (2011 – 2022)
4.1 Patient Numbers Share & Forecast
4.2 Disease-Modifying Therapy (DMT) Patient Numbers Share & Forecast
4.3 By Mode of Administration - Patient Numbers Share & Forecast
5. Europe Multiple Sclerosis Market Share (2011 – 2022)
5.1 By Countries – Unmet Market Share & Forecast
5.2 By Countries – Market Share & Forecast
5.3 By Mode of Administration Market Share & Forecast
6. United Kingdom
6.1 Multiple Sclerosis Patient Numbers (2011 – 2022)
6.1.1 Patient Number & Forecast
6.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
6.2 Multiple Sclerosis Market (2011 – 2022)
6.2.1 Unmet Market & Forecast
6.2.2 Market & Forecast
7. France
7.1 Multiple Sclerosis Patient Number (2011 – 2022)
7.1.1 Patient Number & Forecast
7.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
7.2 Multiple Sclerosis Market (2011 – 2022)
7.2.1 Unmet Market & Forecast
7.2.2 Market & Forecast
8. Germany
8.1 Multiple Sclerosis Patient Number (2011 – 2022)
8.1.1 Patient Number & Forecast
8.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
8.2 Multiple Sclerosis Market (2011 – 2022)
8.2.1 Unmet Market & Forecast
8.2.2 Market & Forecast
9. Italy
9.1 Multiple Sclerosis Patient Number (2011 – 2022)
9.1.1 Patient Number & Forecast
9.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
9.2 Multiple Sclerosis Market (2011 – 2022)
9.2.1 Unmet Market & Forecast
9.2.2 Market & Forecast
10. Spain
10.1 Multiple Sclerosis Patient Number (2011 – 2022)
10.1.1 Patient Number & Forecast
10.1.2 Disease-Modifying Therapy (DMT) Patient Numbers & Forecast
10.2 Multiple Sclerosis Market (2011 – 2022)
10.2.1 Unmet Market & Forecast
10.2.2 Market & Forecast
11. Growth Drivers (Due to data confidentiality, growth drivers have not been disclosed in this table of contents)
11.1 Point no. 1
12. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
12.1 Point no. 1
12.2 Point no. 2
12.3 Point no. 3
13. Appendix
List of Figures:
Figure 2‑1: Europe - Multiple Sclerosis Patient Numbers (Thousand), 2011 - 2016
Figure 2‑2: Europe – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 - 2022
Figure 2‑3: Europe - Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 - 2016
Figure 2‑4: Europe – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 - 2022
Figure 2‑5: Europe – Multiple Sclerosis Injectables Patient Numbers (Thousand), 2011 – 2016
Figure 2‑6: Europe – Forecast for Multiple Sclerosis Injectables Patient Numbers (Thousand), 2017 – 2022
Figure 2‑7: Europe - Multiple Sclerosis Infusions Patient Numbers (Thousand), 2011 – 2016
Figure 2‑8: Europe – Forecast for Multiple Sclerosis Infusions Patient Numbers (Thousand), 2017 – 2022
Figure 2‑9: Europe - Multiple Sclerosis Orals Patient Numbers (Thousand), 2011 – 2016
Figure 2‑10: Europe – Forecast for Multiple Sclerosis Orals Patient Numbers (Thousand), 2017 – 2022
Figure 3‑1: Europe – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 3‑2: Europe – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 3‑3: Europe – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 3‑4: Europe – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 3‑5: Europe – Multiple Sclerosis Injectables Market (Million US$), 2011 – 2016
Figure 3‑6: Europe – Forecast for Multiple Sclerosis Injectables Market (Million US$), 2017 – 2022
Figure 3‑7: Europe – Multiple Sclerosis Infusions Market (Million US$), 2011 – 2016
Figure 3‑8: Europe – Forecast for Multiple Sclerosis Infusions Market (Million US$), 2017 – 2022
Figure 3‑9: Europe – Multiple Sclerosis Orals Market (Million US$), 2011 – 2016
Figure 3‑10: Europe – Forecast for Multiple Sclerosis Orals Market (Million US$), 2017 – 2022
Figure 4‑1: Europe - Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑2: Europe – Forecast for Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑3: Europe - Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑4: Europe – Forecast for Disease-Modifying Therapy (DMT) Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑5: Europe – Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2011 – 2016
Figure 4‑6: Europe – Forecast for Multiple Sclerosis Mode of Administration Patient Numbers Share (Percent), 2017 – 2022
Figure 4‑7: Europe – Multiple Sclerosis Unmet Market Share (Percent), 2011 – 2016
Figure 4‑8: Europe – Forecast for Multiple Sclerosis Unmet Market Share (Percent), 2017 – 2022
Figure 4‑9: Europe – Multiple Sclerosis Market Share (Percent), 2011 – 2016
Figure 4‑10: Europe – Forecast for Multiple Sclerosis Market Share (Percent), 2017 – 2022
Figure 4‑11: Europe – Multiple Sclerosis Market by Mode of Administration Share (Percent), 2011 – 2016
Figure 4‑12: Europe – Forecast for Multiple Sclerosis Market by Mode of Administration Share (Percent), 2017 – 2022
Figure 5‑1: United Kingdom – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 5‑2: United Kingdom – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 5‑3: United Kingdom – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 5‑4: United Kingdom – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 5‑5: United Kingdom – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 5‑6: United Kingdom – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 5‑7: United Kingdom – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 5‑8: United Kingdom – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 6‑1: France – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 6‑2: France – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 6‑3: France – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 6‑4: France – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 6‑5: France – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 6‑6: France – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 6‑7: France – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 6‑8: France – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 7‑1: Germany – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 7‑2: Germany – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 7‑3: Germany – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 7‑4: Germany – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 7‑5: Germany – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 7‑6: Germany – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 7‑7: Germany – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 7‑8: Germany – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 8‑1: Italy – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 8‑2: Italy – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 8‑3: Italy – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 8‑4: Italy – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 8‑5: Italy – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 8‑6: Italy – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 8‑7: Italy – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 8‑8: Italy – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 9‑1: Spain – Multiple Sclerosis Patient Numbers (Thousand), 2011 – 2016
Figure 9‑2: Spain – Forecast for Multiple Sclerosis Patient Numbers (Thousand), 2017 – 2022
Figure 9‑3: Spain – Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2011 – 2016
Figure 9‑4: Spain – Forecast for Multiple Sclerosis Disease-Modifying Therapy (DMT) Patient Numbers (Thousand), 2017 – 2022
Figure 9‑5: Spain – Multiple Sclerosis Unmet Market (Million US$), 2011 – 2016
Figure 9‑6: Spain – Forecast for Multiple Sclerosis Unmet Market (Million US$), 2017 – 2022
Figure 9‑7: Spain – Multiple Sclerosis Market (Million US$), 2011 – 2016
Figure 9‑8: Spain – Forecast for Multiple Sclerosis Market (Million US$), 2017 – 2022
Figure 11‑1: Europe - Number of Neurologists per 100,000 Specialized in MS Vs. Per cent of MS Population Receiving DMDs, 2013
List of Tables
Table 10 1: Europe - Reimbursements for Disease-Modifying Drugs (DMDs), 2013
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com